-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, July 14 hearing recently, Zhuhai United Laboratories' marketing applications for insulin aspart injection and insulin aspart 30 injection have entered the "under review" status and will soon be approved for listing
.
Insulin aspart is the best-selling insulin variety.
In 2020, the total sales in China's public medical institutions and Chinese urban physical pharmacies will exceed 8 billion yuan.
Ganli Pharmaceutical won the first domestic market in 2020
.
Figure 1: Insulin that has recently entered the approval status.
Source: Meinenet MED2.
0 China Drug Review Database Clinical data shows that compared with soluble human insulin, insulin aspart has a faster effect and a shorter duration of action after subcutaneous injection , It can better simulate the physiological insulin secretion pattern after meal, so as to better improve the blood sugar after meal
.
According to data from Minai.
com, in China’s urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) terminals and Chinese urban physical pharmacies , insulin aspart is the TOP1 among insulin and similar drugs.
Varieties, the total sales of the three major terminals in 2020 will exceed 8 billion yuan
.
Figure 2: Insulin aspart sales in physical pharmacies in cities in China (unit: 10,000 yuan) Source: Mynet.
com China’s urban physical pharmacies terminal layout.
In recent years, in Chinese urban physical pharmacies, insulin aspart has been used in insulin and similar drugs The market share is getting higher and higher, rising to 31.
93% in 2020; from the perspective of sales, insulin aspart has exceeded 1 billion yuan in 2017 and rose to 1.
08 billion yuan in 2020, as prescription outflow measures are further implemented , It is expected that the potential of this product in the retail market will increase in the future
.
Table 1: Status of insulin aspart products currently declared for marketing and under review.
Source: Meinenet.
com MED2.
0 Chinese drug review database Ganli Pharmaceutical won the domestic market of insulin aspart injection and insulin aspart 30 injection respectively in 2020 The first, Zhuhai United Laboratories is expected to become the second in China
.
For the above two products, Dongyang Sun Pharmaceuticals has submitted separate marketing applications, both of which are under review and approval
.
At present, Novo Nordisk occupies a high position in the market for this variety.
With the approval of domestic brands one after another, there is huge room for replacing the original research
.
Source: Mi Nei.
com database The review data statistics are as of July 13, if there are any errors or omissions, please correct me
.
.
Insulin aspart is the best-selling insulin variety.
In 2020, the total sales in China's public medical institutions and Chinese urban physical pharmacies will exceed 8 billion yuan.
Ganli Pharmaceutical won the first domestic market in 2020
.
Figure 1: Insulin that has recently entered the approval status.
Source: Meinenet MED2.
0 China Drug Review Database Clinical data shows that compared with soluble human insulin, insulin aspart has a faster effect and a shorter duration of action after subcutaneous injection , It can better simulate the physiological insulin secretion pattern after meal, so as to better improve the blood sugar after meal
.
According to data from Minai.
com, in China’s urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) terminals and Chinese urban physical pharmacies , insulin aspart is the TOP1 among insulin and similar drugs.
Varieties, the total sales of the three major terminals in 2020 will exceed 8 billion yuan
.
Figure 2: Insulin aspart sales in physical pharmacies in cities in China (unit: 10,000 yuan) Source: Mynet.
com China’s urban physical pharmacies terminal layout.
In recent years, in Chinese urban physical pharmacies, insulin aspart has been used in insulin and similar drugs The market share is getting higher and higher, rising to 31.
93% in 2020; from the perspective of sales, insulin aspart has exceeded 1 billion yuan in 2017 and rose to 1.
08 billion yuan in 2020, as prescription outflow measures are further implemented , It is expected that the potential of this product in the retail market will increase in the future
.
Table 1: Status of insulin aspart products currently declared for marketing and under review.
Source: Meinenet.
com MED2.
0 Chinese drug review database Ganli Pharmaceutical won the domestic market of insulin aspart injection and insulin aspart 30 injection respectively in 2020 The first, Zhuhai United Laboratories is expected to become the second in China
.
For the above two products, Dongyang Sun Pharmaceuticals has submitted separate marketing applications, both of which are under review and approval
.
At present, Novo Nordisk occupies a high position in the market for this variety.
With the approval of domestic brands one after another, there is huge room for replacing the original research
.
Source: Mi Nei.
com database The review data statistics are as of July 13, if there are any errors or omissions, please correct me
.
